SG
VRTX icon

Sankala Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Sankala Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Hold
233
– – 0.08% 173
2025
Q4 		$116K Buy
+233
New +$100K 0.09% 162

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sankala Group's VRTX Position: Q1 2026 in Review

Sankala Group held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 233 shares worth $104K. The position accounts for 0.08% of the portfolio, ranked #173.

Sankala Group first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $116K in Q4 2025. 1,692 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Sankala Group held 233 shares of Vertex Pharmaceuticals worth $104K as of Q1 2026.
  • Sankala Group left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.08% of Sankala Group's portfolio in Q1 2026, its #173 holding.
  • Sankala Group first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Sankala Group's Vertex Pharmaceuticals position peaked at $116K in Q4 2025.
  • 1,692 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.